(Q38035660)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

Chronic renal allograft injury: early detection, accurate diagnosis and management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Marta Crespo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Julio Pascual

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Maria J Pérez-Sáez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Marisa Mir

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

17 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

published in

Transplantation Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

280-290

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22902496%20AND%20SRC:MED&resulttype=core&format=json

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN')

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Identifying specific causes of kidney allograft loss.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The natural history of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Chronic renal allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Cardiovascular complications after renal transplantation and their prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

A clinical scoring system highly predictive of long-term kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Assessing kidney function--measured and estimated glomerular filtration rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Limitations of glomerular filtration rate equations in the renal transplant patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Prediction of creatinine clearance from serum creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Evolution of the renal function is a better predictor of long-term survival than serum creatinine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The clinical significance of early proteinuria after renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The renal arterial resistance index and renal allograft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Real-time contrast-enhanced sonography of renal transplant recipients predicts chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Protocol biopsies in renal transplantation: prognostic value of structural monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Subclinical Rejection Associated with Chronic Allograft Nephropathy in Protocol Biopsies as a Risk Factor for Late Graft Loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Transplant glomerulopathy: subclinical incidence and association with alloantibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The pathology of chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Role of donor kidney biopsies in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Time-zero renal biopsy in living kidney transplantation: a valuable opportunity to correlate predonation clinical data with histological abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Polyomavirus nephropathy in native kidneys and renal allografts: an update on an escalating threat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Antibody-mediated organ-allograft rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Transplant glomerulopathy: morphology, associations and mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The significance of subclinical rejection and the value of protocol biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Apoptosis and treatment of chronic allograft nephropathy with everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early elimination of cyclosporine in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Everolimus as Primary Immunosuppression in Kidney Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Conversion to everolimus in maintenance patients--current clinical strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Management of glomerular proteinuria: a commentary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Proteinuria: its clinical importance and role in progressive renal disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Proteinuria after kidney transplantation, relationship to allograft histology and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Chronic renal allograft dysfunction: a role for mycophenolate mofetil?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Advances in diagnosing and managing antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002

Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2012.07.002